Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Disorders of the Female Reproductive System

Disorders of the Female Reproductive System

The female reproductive system can be affected by several disorders, including Premenstrual Syndrome (PMS), Premenstrual Dysphoric Disorder (PMDD), endometriosis, and various forms of cancer. PMS and PMDD are cyclical conditions that cause physical and emotional distress, with symptoms that include edema, mood swings, and food cravings. PMDD is a more severe form of PMS characterized by increased symptom severity that peaks during the luteal phase and tends to improve or resolve shortly after...

Oogenesis

Oogenesis

In human women, oogenesis produces one mature egg cell or ovum for every precursor cell that enters meiosis. This process differs in two unique ways from the equivalent procedure of spermatogenesis in males. First, meiotic divisions during oogenesis are asymmetric, meaning that a large oocyte (containing most of the cytoplasm) and minor polar body are produced as a result of meiosis I, and again following meiosis II. Since only oocytes will go on to form embryos if fertilized, this unequal...

Oogenesis

Oogenesis

Oogenesis, the process of developing egg cells (female gametes), occurs within the ovaries and is fundamental to female fertility. This sequence begins during fetal development when diploid oogonia in the developing ovaries undergo mitotic divisions to produce primary oocytes. By birth, these primary oocytes enter prophase I of meiosis but become arrested in this stage, remaining suspended until puberty.
Each primary oocyte is surrounded by a layer of pre-granulosa cells, forming what is known...

Ovarian Cycle

Ovarian Cycle

The menstrual cycle includes a critical component known as the ovarian cycle, which undergoes two main phases each month—the follicular phase and the luteal phase. The follicular phase is variable and averaging around 14 days. Ovulation, triggered by a surge in luteinizing hormone (LH), marks the transition between the two phases. The second phase, the luteal phase, is relatively consistent, lasting approximately 14 days, and is marked by the activity of the corpus luteum. While a cycle length...

Cushing Syndrome II: Pathophysiology

Cushing Syndrome II: Pathophysiology

Cortisol production is normally governed by the hypothalamic–pituitary–adrenal (HPA) axis, which maintains hormonal balance through tightly regulated feedback mechanisms. Disruption of this regulatory system is central to the development of Cushing syndrome, whether the excess cortisol originates from external medications or internal pathology. Persistent cortisol elevation alters metabolism, immune function, and endocrine signaling, producing the characteristic clinical features of the...

Hormonal Control of the Ovarian Cycle

Hormonal Control of the Ovarian Cycle

The ovarian cycle is meticulously regulated by the hypothalamic-pituitary-gonadal axis. This cycle orchestrates the release of a mature oocyte, essential for reproduction.
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Utility of automated CT perfusion software in acute ischemic stroke with large and medium vessel occlusion.

Annals of clinical and translational neurology·2024

Same author

How to Define Fast and Slow Progressors in Any-Type Occlusion Acute Ischemic Stroke.

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques·2022

Same author

Association of CT-Based Hypoperfusion Index With Ischemic Core Enlargement in Patients With Medium and Large Vessel Stroke.

Neurology·2021

Same author

Protecting thermodynamic stability of protein: The basic paradigm against stress and unfolded protein response by osmolytes.

International journal of biological macromolecules·2021

Same author

Comparison of efficacy of dexamethasone and methylprednisolone in moderate to severe covid 19 disease.

Annals of medicine and surgery (2012)·2020

Same author

Diabetes and Cardiovascular Disease: an Update.

Current diabetes reports·2019

Search research articles

Related Experiment Video

Updated: Jul 13, 2026

Evaluation of Hepatic Glucose Production in a Polycystic Ovary Syndrome Mouse Model

Evaluation of Hepatic Glucose Production in a Polycystic Ovary Syndrome Mouse Model

Published on: March 5, 2022

Polycystic ovarian syndrome.

Khurshid A Khan¹, Sameer Stas, L Romayne Kurukulasuriya

¹Cosmopolitan-International Diabetes and Endocrinology Center, Department of Internal Medicine, University of Missouri-Columbia, Columbia, MO 65212, USA.

Journal of the Cardiometabolic Syndrome

|August 8, 2007

Summary

Polycystic ovary syndrome (PCOS) is a common endocrine disorder in women. Early recognition of metabolic risks like diabetes and heart disease, alongside lifestyle changes and medication, is crucial for managing PCOS complications.

More Related Videos

A Modified Technique for Inducing Polycystic Ovary Syndrome in Mice

A Modified Technique for Inducing Polycystic Ovary Syndrome in Mice

Published on: July 5, 2024

A Hyperandrogenic Mouse Model to Study Polycystic Ovary Syndrome

A Hyperandrogenic Mouse Model to Study Polycystic Ovary Syndrome

Published on: October 2, 2018

Related Experiment Videos

Last Updated: Jul 13, 2026

Evaluation of Hepatic Glucose Production in a Polycystic Ovary Syndrome Mouse Model

Evaluation of Hepatic Glucose Production in a Polycystic Ovary Syndrome Mouse Model

Published on: March 5, 2022

A Modified Technique for Inducing Polycystic Ovary Syndrome in Mice

A Modified Technique for Inducing Polycystic Ovary Syndrome in Mice

Published on: July 5, 2024

A Hyperandrogenic Mouse Model to Study Polycystic Ovary Syndrome

A Hyperandrogenic Mouse Model to Study Polycystic Ovary Syndrome

Published on: October 2, 2018

Area of Science:

Reproductive endocrinology
Metabolic syndrome

Background:

Polycystic ovary syndrome (PCOS) is the most prevalent reproductive endocrine disorder in women of reproductive age.
Key features include insulin resistance, androgen excess, and abnormal gonadotropin dynamics, with genetic predisposition.
PCOS increases the risk of serious health issues such as diabetes, hypertension, dyslipidemia, and cardiovascular disease.

Purpose of the Study:

To highlight the significant, often unrecognized, health risks associated with PCOS.
To emphasize the importance of early detection and management of metabolic complications.
To review current and promising therapeutic strategies for PCOS.

Main Methods:

Review of current medical literature on PCOS etiology, risks, and management.
Analysis of the interplay between insulin resistance, adiposity, and cardiometabolic sequelae.
Evaluation of lifestyle modifications and pharmacological interventions.

Main Results:

Insulin resistance and adiposity are central to the increased risk of diabetes, hypertension, dyslipidemia, and cardiovascular disease in women with PCOS.
Despite substantial risks, awareness among affected women remains low.
Lifestyle interventions (diet, exercise, weight loss) are paramount.
Pharmacological agents like metformin and thiazolidinediones show promise for managing cardiometabolic aspects.

Conclusions:

Early identification and management of metabolic complications in PCOS are critical for preventing long-term adverse health outcomes.
A comprehensive approach integrating lifestyle changes and pharmacotherapy is essential for effective PCOS management.
Increased awareness of PCOS-related risks among women and clinicians is needed.